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Pharmacodynamic Effects of the Murine p75-Fc
Fusion Protein in Mice
Yi-Ling Hu1, Helen Y. Kim1, Tadahiko Kohno1 and Sanjay D. Khare1
Overproduction of inflammatory mediators, such as tumor necrosis factor (TNF), is key to the development and
maintenance of inflammatory processes. Etanercept is a soluble TNF receptor fusion protein used in the
treatment of various chronic inflammatory diseases, including rheumatoid arthritis and psoriasis. This study
investigated the effects of murine p75-Fc, a soluble TNF receptor protein, on TNF-induced IL-6 production in
mice. Six groups of mice received either murine p75-Fc (0.15, 0.50, 1.5, 5, and 15 mg/kg) or phosphate-buffered
saline. Three days later, mice were injected intravenously with 10 mg of murine TNF and blood samples were
taken after 3 hours. Serum IL-6 and TNF were measured by ELISA. Mice treated with 5 and 15 mg/kg murine p75-
Fc demonstrated complete inhibition of TNF-induced IL-6 production. Murine p75-Fc (1.5 mg/kg) resulted in a
partial but significant reduction of TNF-induced IL-6 production. No TNF was detected in 5 and 15 mg/kg murine
p75-Fc-treated mice, except one in the 5 mg/kg dose group. In conclusion, murine p75-Fc completely inhibits
TNF-induced IL-6 production in mice.
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INTRODUCTION
Etanercept (Amgen Inc., Thousand Oaks, CA) is a soluble
receptor-IgG1 (tumor necrosis factor receptor (TNFR)2-
IgG1Fc) fusion protein used in the treatment of various
chronic inflammatory diseases in humans, including
moderate-to-severe rheumatoid arthritis, moderate-to-
severe juvenile rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis, and moderate-to-severe plaque psoriasis.
To be able to study the effects of the soluble receptor
fusion protein in mouse models, including those that mimic
human granulomatous infections, a murine p75-Fc fusion
protein was constructed (Kim et al., 2006). This article
discusses the pharmacodynamic effects of this molecule in
mice.
TNF has long been known to induce the production of
interleukin-6 (IL-6) (Wilbrink et al., 1991; Kozawa et al.,
1997; Machelon et al., 1997; Alonzi et al., 1998; Mindrescu
et al., 2000). In this experiment, we studied the dose of
murine p75-Fc required to inhibit TNF-induced IL-6 produc-
tion in mice.
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Figure 1. The effect of murine p75-Fc fusion protein in mice. (a) IL-6 production and (b) TNF levels. Horizontal lines indicate mean values.
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RESULTS
Mice treated with 5 and 15 mg/kg of murine p75-Fc
demonstrated complete inhibition of TNF-induced IL-6
production 72 hours after dosing (Figure 1a). Partial but
significant reduction of TNF-induced IL-6 production was
observed in mice treated with the 1.5 mg/kg dose compared
with that seen in the animals in the phosphate-buffered saline
control group. No reduction in TNF-induced IL-6 production
was seen in the mice that received 0.50 or 0.15 mg/kg of
murine p75-Fc (Figure 1a).
No free murine TNF was detected in animals injected with
15 mg/kg murine p75-Fc. A similar effect was also observed
in all animals, except one treated at the 5 mg/kg dose of
murine p75-Fc (Figure 1b).
DISCUSSION
Injection of the murine p75-Fc fusion protein completely
inhibited murine TNF-induced IL-6 and, in most cases,
eliminated detectable TNF from blood at both the 5 and
15 mg/kg doses.
MATERIALS AND METHODS
On day 0, five groups of BALB/c mice (The Jackson Laboratory, Bar
Harbor, ME) were dosed with the murine p75-Fc fusion protein in
the following doses: 0.15, 0.50, 1.5, 5, and 15 mg/kg; a sixth group
of control mice received phosphate-buffered saline (Table 1).
Three days later, the mice were injected intravenously with 10mg
of murine TNF. Three hours later, the animals were bled and their
serum samples were measured by enzyme-linked immunosorbent
assay (ELISA) for TNF-induced IL-6 production.
Further, murine TNF levels were also measured by ELISA to gain
understanding of TNF not sequestered by the drug (murine p75-Fc).
All experimental methodology was approved by Amgen Inc.
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Table 1. Study groups
Group
Number
of mice Treatment
Dose of murine
p75-Fc (mg/kg)
1 5 Murine p75-Fc 15
2 5 Murine p75-Fc 5
3 5 Murine p75-Fc 1.5
4 5 Murine p75-Fc 0.5
5 4 Murine p75-Fc 0.15
6 5 PBS control —
PBS, phosphate-buffered saline.
www.jidonline.org 51
Y-L Hu et al.
Murine p75-Fc Fusion Protein in Mice
